Drug development for brain disorders: Why sex matters: Ischemic stroke across sexes: what is the status quo?

Drug development for brain disorders: Why sex matters: Ischemic stroke across sexes: what is the status quo? Front Neuroendocrinol. 2018 May 10;: Authors: Liberale L, Carbone F, Montecucco F, Gebhard C, Lüscher TF, Wegener S, Camici GG Abstract Stroke prevalence is expected to increase in the next decades due to the aging of the Western population. Ischemic stroke (IS) shows an age- and sex-dependent distribution in which men represent the most affected population within 65 years of age, being passed by post-menopausal women in older age groups. Furthermore, a sexual dimorphism concerning risk factors, presentation and treatment of IS has been widely recognized. In order to address these phenomena, a number of issue have been raised involving both socio-economical and biological factors. The latter can be either dependent on sex hormones or due to intrinsic factors. Although women have poorer outcomes and are more likely to die after a cerebrovascular event, they are still underrepresented in clinical trials and this is mirrored by the lack of sex-tailored therapies. A greater effort is needed in the future to ensure improved treatment and quality of life to both sexes. PMID: 29753797 [PubMed - as supplied by publisher]
Source: Frontiers in Neuroendocrinology - Category: Endocrinology Authors: Tags: Front Neuroendocrinol Source Type: research